Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1994 Mar;69(3):562–565. doi: 10.1038/bjc.1994.102

A prospective study of serum tumour markers carcinoembryonic antigen, carbohydrate antigens 50 and 242, tissue polypeptide antigen and tissue polypeptide specific antigen in the diagnosis of pancreatic cancer with special reference to multivariate diagnostic score.

P A Pasanen 1, M Eskelinen 1, K Partanen 1, P Pikkarainen 1, I Penttilä 1, E Alhava 1
PMCID: PMC1968866  PMID: 8123488

Abstract

The aim of this study was to assess by a stepwise multivariate discriminant analysis the value of four current serum tumour markers - carcinoembryonic antigen (CEA), carbohydrate antigen (CA) 50 and CA 242 and tissue polypeptide antigen (TPA) - and a new serum tumour marker, tissue polypeptide specific antigen (TPS), in the diagnosis of pancreatic cancer. The serum values were measured in a prospective series of patients with jaundice, with unjaundiced cholestasis and with a suspicion of chronic pancreatitis or a pancreatic tumour (n = 193). There were 24 patients with a cancer of the pancreas and two patients with a cancer of the papilla of Vater in this series. Our results showed that CA 50 (P < 0.001) and TPA (P < 0.01) were the best marker tests in predicting pancreatic malignancy. Also, the TPS (P = 0.07) and CA 242 (P = 0.08) tests showed marginally significant independent discriminating power, while the CEA test did not (P = 0.12). In order to sum up the contributions of different markers, a diagnostic score (DSI) was developed. The discrimination function was: DS1 = CA 50 x 1.75 + TPA x 0.62 + TPS x (-0.37) + CA 242 x (-1.21). The sensitivity of DS1 in detecting pancreatic cancer was 36% with a specificity of 90% and an efficiency of 82%. When the combination of CA 50 and TPA was used as a test, the discrimination function (DS2) was: DS2 = CA 50 x 0.69 + TPA x 0.67. The sensitivity of DS2 was 44% with a 88% specificity and an efficiency of 82%. According to this analysis, the further advantage gained by a computer-aided scoring system seems to be limited, since despite the considerably high specificity and efficiency its sensitivity remained low. In the present analysis the best combination in diagnosing pancreatic cancer was the combination of CA 50 and TPA.

Full text

PDF
562

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Albert A. On the use and computation of likelihood ratios in clinical chemistry. Clin Chem. 1982 May;28(5):1113–1119. [PubMed] [Google Scholar]
  2. BJORKLUND B., BJORKLUND V. Antigenicity of pooled human malignant and normal tissues by cyto-immunological technique; presence of an insoluble, heat-labile tumor antigen. Int Arch Allergy Appl Immunol. 1957;10(3):153–184. [PubMed] [Google Scholar]
  3. Benini L., Cavallini G., Zordan D., Rizzotti P., Rigo L., Brocco G., Perobelli L., Zanchetta M., Pederzoli P., Scuro L. A. A clinical evaluation of monoclonal (CA19-9, CA50, CA12-5) and polyclonal (CEA, TPA) antibody-defined antigens for the diagnosis of pancreatic cancer. Pancreas. 1988;3(1):61–66. doi: 10.1097/00006676-198802000-00011. [DOI] [PubMed] [Google Scholar]
  4. Björklund B., Björklund V. Specificity and basis of the tissue polypeptide antigen. Cancer Detect Prev. 1983;6(1-2):41–50. [PubMed] [Google Scholar]
  5. Goldberg D. M., Ellis G. Mathematical and computer-assisted procedures in the diagnosis of liver and biliary tract disorders. Adv Clin Chem. 1978;20:49–128. doi: 10.1016/s0065-2423(08)60020-7. [DOI] [PubMed] [Google Scholar]
  6. Haglund C., Kuusela P., Jalanko H., Roberts P. J. Serum CA 50 as a tumor marker in pancreatic cancer: a comparison with CA 19-9. Int J Cancer. 1987 Apr 15;39(4):477–481. doi: 10.1002/ijc.2910390412. [DOI] [PubMed] [Google Scholar]
  7. Haglund C., Lindgren J., Roberts P. J., Kuusela P., Nordling S. Tissue expression of the tumour associated antigen CA242 in benign and malignant pancreatic lesions. A comparison with CA 50 and CA 19-9. Br J Cancer. 1989 Dec;60(6):845–851. doi: 10.1038/bjc.1989.377. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Haglund C., Roberts P. J., Jalanko H., Kuusela P. Tumour markers CA 19-9 and CA 50 in digestive tract malignancies. Scand J Gastroenterol. 1992;27(3):169–174. doi: 10.3109/00365529208999944. [DOI] [PubMed] [Google Scholar]
  9. Haglund C. Tumour marker antigen CA125 in pancreatic cancer: a comparison with CA19-9 and CEA. Br J Cancer. 1986 Dec;54(6):897–901. doi: 10.1038/bjc.1986.259. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Kuusela P., Haglund C., Roberts P. J. Comparison of a new tumour marker CA 242 with CA 19-9, CA 50 and carcinoembryonic antigen (CEA) in digestive tract diseases. Br J Cancer. 1991 Apr;63(4):636–640. doi: 10.1038/bjc.1991.146. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Köhler G., Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975 Aug 7;256(5517):495–497. doi: 10.1038/256495a0. [DOI] [PubMed] [Google Scholar]
  12. Masson P., Pålsson B., Andrén-Sandberg A. Cancer-associated tumour markers CA 19-9 and CA-50 in patients with pancreatic cancer with special reference to the Lewis blood cell status. Br J Cancer. 1990 Jul;62(1):118–121. doi: 10.1038/bjc.1990.241. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Pasanen P. A., Eskelinen M., Partanen K., Pikkarainen P., Penttilä I., Alhava E. Clinical evaluation of a new serum tumour marker CA 242 in pancreatic carcinoma. Br J Cancer. 1992 May;65(5):731–734. doi: 10.1038/bjc.1992.154. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Pasanen P. A., Eskelinen M., Partanen K., Pikkarainen P., Penttilä I., Alhava E. Receiver operating characteristic (ROC) curve analysis of the tumour markers CEA, CA 50 and CA 242 in pancreatic cancer; results from a prospective study. Br J Cancer. 1993 Apr;67(4):852–855. doi: 10.1038/bjc.1993.156. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Pasanen P. A., Partanen K., Pikkarainen P., Alhava E., Pirinen A., Janatuinen E. Diagnostic accuracy of ultrasound, computed tomography, and endoscopic retrograde cholangiopancreatography in the detection of obstructive jaundice. Scand J Gastroenterol. 1991 Nov;26(11):1157–1164. doi: 10.3109/00365529108998608. [DOI] [PubMed] [Google Scholar]
  16. Tian F., Appert H. E., Myles J., Howard J. M. Prognostic value of serum CA 19-9 levels in pancreatic adenocarcinoma. Ann Surg. 1992 Apr;215(4):350–355. doi: 10.1097/00000658-199204000-00008. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES